Turning Point Therapeutics, which is developing targeted cancer drugs for patients whose tumors resist other precision therapies, has outlined plans for an IPO.
The company, which started operations in 2014, has raised nearly $148 million since inception. It is headed by Athena Countouriotis, who joined the company in May as its chief medical officer, then was promoted to chief executive in September.
The San Diego biotech is developing what it describes as a “next-generation” drug as a treatment for cancers associated with genetic variations that alter the enzymes ALK, ROS1, and TRK. Drugs already exist for some cancers associated with those… Read more »
UNDERWRITERS AND PARTNERS